Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02290951
Title Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications

B-cell lymphoma

Therapies

Rituximab

Odronextamab

Age Groups: adult | senior
Covered Countries USA | FRA | DEU

Facility Status City State Zip Country Details
University of California, Irvine Recruiting Orange California 92868 United States Details
Stanford University Recruiting Stanford California 94305 United States Details
Moffitt Cancer Center Completed Tampa Florida 33612 United States Details
Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel) Recruiting Boston Massachusetts 02215 United States Details
Mayo Clinic Recruiting Rochester Minnesota 55905 United States Details
Rutgers Cancer Institute of New Jersey Recruiting New Brunswick New Jersey 08901 United States Details
Memorial Sloan Kettering Cancer Center Completed New York New York 10065 United States Details
Weill Cornell Medical College Recruiting New York New York 10065 United States Details
Centre Hospitalier Lyon-Sud Hospices Civils de Lyon Recruiting Pierre Benite Cedex 69495 France Details
CHU Hôpital Lyon Sud Recruiting Lyon France Details
Universitatsklinikum Wurzburg Recruiting Wurzburg Germany Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field